Hepatotoxicity of Antitubercular Treatments: Rationale for Monitoring Liver Status

Drug Safety

Volumn 15, Issue 6, 1996, Pages 394-405

  Durand, François ^a   Jebrak, Gilles ^a   Pessayre, Dominique ^a   Fournier, Michel ^a   Bernuau, Jacques ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMIKACIN; AMINOSALICYLIC ACID; AMINOTRANSFERASE; CYTOCHROME P450; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PARACETAMOL; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; INTERSTITIAL NEPHRITIS; JAUNDICE; LIVER FAILURE; LIVER FUNCTION; LIVER NECROSIS; LIVER TOXICITY; NEPHROTOXICITY; OPTIC NERVE DISEASE; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VIRUS HEPATITIS;

ANTITUBERCULAR AGENTS; HEPATITIS, TOXIC; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TRANSAMINASES; TUBERCULOSIS;

EID: 0030459135     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615060-00004     Document Type: Article

References (62)

1. Jereb JA, Kelly GD, Dooley SW, et al. Tuberculosis morbidity in the United States: final data. MMWR Morb Mortal Wkly Rep 1991; 40 (SS-3): 23-7
2. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multi-drug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328: 1137-44
3. David HL. Probability distribution of drug resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-4
4. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514-21
5. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 146: 1623-33
6. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644-50
7. World Health Organization. Treatment of tuberculosis: guidelines for national programs. Geneva: World Health Organisation, 1993
8. Gulliford M, Mackay AD, Prowse K. Cholestatic jaundice caused by ethambutol [letter]. Br Med J 1986; 292: 866
9. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79: 1-12
10. Schraer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 1: 1113-20
11. Black M, Mitchell JR, Zimmerman HJ. Isoniazid associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289-302
12. Thomas PA, Mozes MF, Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 1979; 114: 597-9
13. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazid associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972; 106: 357-65
14. Bailey WC, Taylor SL, Dascomb HE, et al. Disturbed hepatic function during isoniazid chemoprophylaxis. Am Rev Respir Dis 1973; 107: 523-9
15. Byrd CR, Horn BR, Solomon DA, et al. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1,000 patients. JAMA 1979; 241: 1239-41
16. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-relaled hepatitis: a US public health service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001
17. Mitchell JR, Zimmerman HJ, Ishak KJ, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181-92
18. Cohen R, Kalser MH, Thomson RV. Fatal hepatic necrosis secondary to isoniazid therapy. JAMA 1961; 176: 877-9
19. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494-7
20. Farrell GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994
21. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferases induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6: 295-8
22. Mitchell JR, Long MW, Thorgeirsson U, et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68: 181-90
23. Pessayre D, Bentata M, Degott C, et al. Isoniazid rifampicin induced fulminant hepatitis: a possible consequence of enhancement of hepatotoxicity by enzyme induction. Gastroenterology 1977; 72: 284-9
24. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21: 929-32
25. Timbrell JA, Mitchell JR, Snodgrass WR, et al. Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213: 364-9
26. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and significance for the treatment of tuberculosis. Clin Pharm Ther 1976; 19: 610-24
27. Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129: 58-61
28. Martinez-Roig A, Cami J, Llorens-Terol J, et al. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics 1986; 77: 912-5
29. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5: S440-5
30. Scheuer PJ, Summerfield JA, Lal S, et al. Rifampicin hepatitis: a clinical and histological study. Lancet 1974; I: 421-5
31. Poupon RY, Meyniel D, Petit J, et al. Hépatite cholestatique au cours d'un traitement par l'INH et la rifampicine; arguments en faveur de l'hépatotoxicité de la rifampicine. Ann Med Interne (Paris) 1979; 130: 371-5
32. Furet Y, Metman EH, Bertrand J, et al. Hépatite mixte à la rifamycine SV [letter]. Therapie 1986; 41 405
33. McDermott W, Ormond L, Muschenheim C, et al. Pyrazinamide and isoniazid in tuberculosis. Am Rev Tuberc 1954; 69: 319-33
34. Singh J, Aora A, Garg PK, et al. Antituberculous treatment induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-62
35. Pretet S, Perdrizet S. La toxicité du pyrazinamide dans les traitements antituberculeux. Rev Fr Mal Respir 1980; 8: 307-20
36. Snider DF, Long MW, Cross FS, et al. Six months' isoniazid and rifampin therapy for pulmonary tuberculosis: report of a USPHS co-operative trial. Am Rev Respir Dis 1984; 129: 573-9
37. Singapore Tuberculosis Services/British Medical Research Council. Clinical trial of six-month regimens of chemotherapy given intermittently in the continuation phase of the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985; 132: 374-8
38. Geiter LJ, O'Brien RJ, Snider DE. Short-course chemotherapy of pulmonary tuberculosis; preliminary results of USPHS therapy trial 21 [abstract]. Am Rev Respir Dis 1986; 133: A205
39. Van Aalderen WMC, Knoester H, Knol K. Fulminant hepatitis during treatment with rifampicin, pyrazinamide and ethambutol. Eur J Pediatr 1987; 146: 290-1
40. Whittington RM. Fatal hepatotoxicity of antitubercular chemotherapy. Lancet 1991; 338: 1083-4
41. Danan G, Pessayre D, Larrey D, et al. Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again [letter]. Lancet 1981; II: 1056
42. Roden S, Lagneau M, Homasson JP. Hépatite fulminante au pyrazinamide [letter]. Rev Pharm Clin 1990; 46: 43
43. Stricker BHC. Drug-induced hepatic injury, 2nd ed. Amsterdam: Elsevier, 1992: 237-47
44. Hautekeete ML, Kockx MM, Naegels S, et al. Cholestatic hepatitis related to quinolones: a report of 2 cases. J Hepatol 1995; 23: 759-63
45. Simpson DG, Walker JH. Hypersensitivity to para-aminosalicylic acid. Am J Med 1960; 29: 297-306
46. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculous therapy: clinical profile and reintroduction therapy. J Clin Gastroenterol 1996; 22: 211-4
47. British Thoracic Association. A controlled trial of six months' chemotherapy in pulmonary tuberculosis: first report: results during chemotherapy. Br J Dis Chest 1981; 75: 141-53
48. Lees AW, Allan GW, Smith J, et al. Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy. Tubercle 1971; 52: 182-90
49. Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118: 461-6
50. Steele MA, Burk RF, Desprez MN. Toxic hepatitis with isoniazid and rifampicin: a meta-analysis. Chest 1991; 99: 465-71
51. Jenner PJ, Ellerd GA. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle 1989; 70: 93-101
52. Horn DL, Hewlett D, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis [letter]. N Engl J Med 1994; 330: 1241
53. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990; 113: 799-800
54. Nolan CM,Sandblo RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105: 408-11
55. Ozick LA, Lee TP, Jacob L, et al. Early hepatotoxicity from antituberculous treatment in alcoholics and AIDS patients [abstract]. Hepatology 1991; 14: 275A
56. Cross FS, Long MW, Banner AS, et al. Rifampicin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a US public health service cooperative therapy trial. Am Rev Respir Dis 1980; 122: 349-53
57. Franks AL, Binkin NJ, Snider DE, et al. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989; 104: 151-5
58. Kumar A, Misra PK, Mehrotra R, et al. Hepatotoxicity of rifampicin and isoniazid: is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143: 1350-2
59. Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampicin induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502-4
60. MouldingTS, Redeker AG, Kanel GC. Twenty isoniazid deaths in one state. Am Rev Respir Dis 1989; 140: 700-5
61. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97-106
62. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculous drugs. Thorax 1996; 51: 111-3